2022 American Transplant Congress
Predicted Performance of Bayesian-Based Precision Dosing Software for Tacrolimus
*Purpose: Bayesian-based precision dosing software (BPDS) has been utilized for therapeutic drug monitoring to optimize medication use. However, BPDS for tacrolimus (TAC) is not routinely…2022 American Transplant Congress
Evaluation of Crushed Posaconazole Delayed Release Tablets in Lung Transplant Recipients
*Purpose: We hypothesized that crushed posaconazole delayed release (POSA DR) tablets can reach therapeutic levels in lung transplant recipients who are at risk for invasive…2022 American Transplant Congress
Conversion from Immediate to Extended-Release Tacrolimus (LCP-Tac) Six Months After Renal Transplantation Optimizes Safety and Efficacy
*Purpose: LCP-Tac is a once daily formulation of tacrolimus indicated for prevention of rejection in kidney transplant recipients (KTRs) that may have less variability and…2022 American Transplant Congress
Impact of African American Race on Lcp-Tac Dosing and Clinical Outcomes
Medical University of South Carolina, Charleston, SC
*Purpose: The goal of this study was to assess the impact of African American (AA) race on the conversion ratio from Tac-IR to LCP-Tac, while…2022 American Transplant Congress
Effectiveness and Limitations of PK Analysis in Optimization of Immunosuppressive Therapy for Kidney Transplantation
Division of Kidney Transplantation, Department of Surgery, Aichi Medical University, Nagakute, Japan
*Purpose: In recent years, significant improvement in organ transplant outcomes have been achieved by using multidrug therapy with several immune monitoring, but the complexity of…2021 American Transplant Congress
Evaluate the Effect of Cresemba (isavuconazonium Sulfate) Capsule and Noxafil (posaconazole) Delayed Release Tablets on Tacrolimus Dose to Concentration (D/C) Ratios in Lung Transplant Recipients
*Purpose: Evaluate the effect of Cresemba (isavuconazonium sulfate) capsule and Noxafil (posaconazole) delayed release tablet on tacrolimus dose to concentration (D/C) ratio in lung transplant.*Methods:…2021 American Transplant Congress
Pharmacokinetic Analysis of Direct Acting Antiviral Use on Weight-Adjusted FK506 Trough/dose Ratios in Obese Kidney Transplant Recipients
*Purpose: Using hepatitis C viremic (HCV) organs in kidney transplant recipients(KTRs) is very important to decrease the number of patients on the waiting list. Direct…2021 American Transplant Congress
De-novo Use Comparison Between Extended-release Once-daily Tacrolimus (Envarsus Xr®) and Immediate-release Twice-daily Tacrolimus (Prograf®) – A Single Center’s Experience
*Purpose: Envarsus XR® is approved for de-novo use post-kidney transplantation at a higher starting dose (0.14mg/kg/day) as compared with Prograf® (0.1 mg/kg/day) despite better bioavailability.…2021 American Transplant Congress
Elexacaftor/ivacaftor/tezacaftor in Lung Transplant Recipients: A Case Series
1University of Chicago Medicine, Chicago, IL, 2Roosevelt University, Chicago, IL
*Purpose: Little data is published describing the safety or efficacy of elexacaftor/ivacaftor/tezacaftor in lung transplant recipients. Even though it is not expected to offer pulmonary…2021 American Transplant Congress
The Impact of De Novo Dose-Adjustment Strategies with Tacrolimus XR (LCP-Tac) in Kidney Transplant Recipients
Medical University of South Carolina, Charleston, SC
*Purpose: LCP-Tac is a once daily formulation of tacrolimus indicated for the prophylaxis of rejection in de novo kidney transplant recipients. It provides less variable…
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 12
- Next Page »